| Objective To investigate the efficacy of clostridium butyricum and alendronate sodium in inflammatory bowel disease complicated with osteoporosis (IBDCO) patients and the effects on bone metabolism, inflammatory factors and intestinal flora. Methods 80 IBDCO patients were randomly divided into the control group and observation group. Besides conventional treatments, the control group was given alendronate sodium, while the other was additionally given lived combined clostridium butyricum and bifidobacterium capsules for 3 months. Curative efficacy, bone mineral density (BMD), bone metabolism indices, levels of inflammatory factors and intestinal flora were compared between two groups. Results Compared to the control group after 3 months, the observation group had higher efficacy (95.0% vs 77.5%), higher BMD of lumbar vertebra, femur neck and Wards triangle, higher levels of bone alkaline phosphatase, osteocalcin, lower level of C-terminal telopeptide of type-I collagen, lower levels of IL-6 and IL-17, lower content of bacillus coli and higher contents of bacillus bifida and lactobacillus in feces (all P<0.05). Conclusion Clostridium butyricum combined with alendronate sodium has high short-term curative efficacy for IBDCO patients, which can increase BMD, improve bone metabolism indices, alleviate inflammatory reaction and regulate intestinal flora. It is suitable for clinical application. |